--This blog post celebrates the one-year anniversary of the launch of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. When we launched the Bloomberg~Kimmel Institute for Cancer… Read More »Making Real and Measureable Progress with Immunotherapy
A decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put… Read More »Top Questions Ahead for Cancer Immunotherapy
More than 20 years ago, when Johns Hopkins scientists Bert Vogelstein, Ken Kinzler and their colleagues linked certain cancers to mutations in genes that repair DNA,… Read More »Research from Bloomberg-Kimmel Institute Among Best of #ASCO2017
Immunotherapy has become one of the hottest areas of cancer research, and the number of cancers successfully treated by immunotherapy is growing. Nearing the end… Read More »5 Things We Learned About Immunotherapy This Year
A ceremony was held yesterday at the White House to sign the 21st Century Cures Act, which authorizes $4.8 billion in National Institutes of Health funding… Read More »President Obama Signs 21st Century Cures Act
In a head-to-head comparison between the immunotherapy drug pembrolizumab and standard chemotherapy as a first-line therapy for advanced nonsmall cell lung cancer, patients taking pembrolizumab had… Read More »Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients
The University of Chicago and Johns Hopkins' Bloomberg~Kimmel Institute for Cancer Immunotherapy have published a pair of studies looking at biomarkers involved in the immune… Read More »Studies track how the immune system responds to tumors
This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel… Read More »A perspective on an immunotherapy clinical trial
Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, is a pioneer in the search for biomarkers that predict responses to immunotherapy.… Read More »What Makes Some Kidney Cancers Resistant to Immunotherapy?
So-called anti-PD-1 drugs, which block the interaction between proteins on cancer and immune cells, are currently approved by the Food and Drug Administration for certain… Read More »Study: First Hints that Anti-PD-1 Therapy May Help Men with Advanced Prostate Cancer